Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).
- Mechanism
- Curator reviewed
Siplizumab has been shown to cause depletion of T-cells. It is therefore considered to be an immunomodulator in clinical settings where the depletion of T-cells may have clinical benefits, such as certain autoimmune diseases and T-cell cancers. In addition, preclinical studies have also suggested that siplizumab, by binding to the CD2 receptor, may selectively produce cell death and reduce cancerous cells.
- Primary indication
- Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).Curator reviewed
- Code names
- MEDI-507
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Siplizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account